Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for pneumococcal pneumonia

Journal of Infectious Diseases

Volumn 182, Issue 1, 2000, Pages 158-167

  Musher, Daniel M ^a,b   Phan, Hoang M ^a,b   Watson, David A ^a,b   Baughn, Robert E ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HOSPITALIZATION; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; LOBAR PNEUMONIA; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; DISEASE MODELS, ANIMAL; HOSPITALIZATION; HUMANS; IMMUNOGLOBULIN M; LEUKOCYTES, MONONUCLEAR; MICE; OPSONIN PROTEINS; PATIENT ADMISSION; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; POLYSACCHARIDES, BACTERIAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 0033914636     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315697     Document Type: Article

References (41)

1. 1. Heffron R. Pneumonia: with special reference to pneumococcus lobar pneumonia. Cambridge, MA: Harvard University Press, 1979.
2. 2. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis 1981; 3(Suppl):S1-S17.
3. 3. Musher DM, Watson DA, Dominguez E. Pneumococcal vaccination: work to date and future prospects. Am J Med Sci 1990;300:45-52.
4. 4. Rubins JB, Puri AKG, Loch J, et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 1998;179:431-40.
5. 5. Steiner S, Musher DM, Pais LB, et al. Functional antibody activity against Streptococcus pneumoniae in elderly individuals vaccinated with the 23-valent polysaccharide pneumococcal vaccine. Clin Infect Dis 1999;29: 281-8.
6. 6. Schiffman G, Douglas RM, Bonner MJ, Robbins M, Austrian R. A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques. J Immunol Methods 1980;33:133-44.
7. 7. Musher DM, Johnson B Jr, Watson DA. Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun 1990;58:3871-6.
8. 8. Siber GR, Priehs C, Madore DV. Standardization of antibody assays for measuring the response to pneumococcal infection and immunization. Pediatr Infect Dis J 1989;8:S84-S91.
9. 9. Musher DM, Luchi M, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with nontype-specific cell wall polysaccharide. J Infect Dis 1990;161: 728-35.
10. 10. Musher DM, Groover JE, Rowland JM, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis 1993;17:66-73.
11. 11. Ertugrul N, Rodriguez-Barradas MC, Musher DM, et al. BOX-polymerase chain reaction-based DNA analysis of nonserotypeableStreptococcus pneumoniaeimplicated in outbreaks of conjunctivitis. J Infect Dis 1997; 176:1401-5.
12. 12. Musher DM, Groover JE, Reichler MR, et al. Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during pneumonia outbreaks: association with nasopharyngeal colonization. Clin Infect Dis 1997;24:441-6.
13. 13. Baughn RE, McNeely MC, Jorizzo JL, Musher DM. Characterization of the antigenic determinants and host components in immune complexes from patients with secondary syphilis. J Immunol 1986;136:1406-14.
14. 14. Bandres JC, Trial J, Musher DM, Rossen RD. Increased phagocytosis and generation of reactive oxygen products by neutrophils and monocytes of men with stage 1 human immunodeficiency virus infection. J Infect Dis 1993;168:75-83.
15. 15. Musher DM, Johnson BJ, Watson DA. Antibody to Streptococcus pneumoniae measured by ELISA or RIA but adsorbed by cell wall constituents does not protect mice against pneumococcal challenge. Infect Immun 1990;58:3871-6.
16. 16. Morch E. Serological studies on the pneumococci. Copenhagen: Humphrey Milford-Oxford University Press, 1943.
17. 17. Mufson MA, Kruss DM, Wasil RE, Metzger WI. Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch Intern Med 1974;134:505-10.
18. 18. Watanakunakorn C, Bailey TA. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992-1996. A detailed analysis of 108 cases. Arch Intern Med 1997;157:1965-71.
19. 19. Musher DM, Alexandraki I, Graviss EA, et al. Bacteremic and nonbacteremic pneumococcal pneumonia: a prospective study. Medicine (Baltimore) 2000;79:210-21.
20. 20. Alexander JE, Lock R, Peeters CC, et al. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 1994;62: 5683-8.
21. 21. Boulnois GJ. Pneumococcal proteins and the pathogenesis of disease caused by Streptococcus pneumoniae. J Gen Microbiol 1992;138:249-59.
22. 22. Briles DE, Hollingshead SK, Swiatlo E, et al. PspA and PspC: their potential for use as pneumococcal vaccines. Microb Drug Resist 1997;3:401-8.
23. 23. Paton JC, Berry AM, Lock A. Molecular analysis of putative pneumococcal virulence proteins. Microb Drug Resist 1997;3:3-10.
24. 24. Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;315:1318-27.
25. 25. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
26. 26. Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 1986;154:245-56.
27. 27. Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996;173:387-93.
28. 28. Musher DM, Groover JE, Graviss EA, Baughn RE. The lack of association between aging and postvaccination levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae. Clin Infect Dis 1996;22: 165-7.
29. 29. Nahm MH, Olander JV, Magyarlaki M. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J Infect Dis 1997;176:698-703.
30. 30. Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect Immun 1999;67:2366-70.
31. 31. Vitharsson G, J́onsdóttir I, Jónsson S, Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J Infect Dis 1994;170:592-9.
32. 32. Yee AMF, Ng SC, Sobel RE, Salmon JE. FcγRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. Arthritis Rheum 1997;40:1180-1.
33. 33. Yee AMF, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcγRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:25-8.
34. 34. Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fcγ receptor IIB: independent mechanisms for differences in human phagocyte function. J Clin Invest 1992;89:1274-81.
35. 35. Rodriguez ME, van der Pol WL, Sanders LAM, van de Winkel JGJ. Crucial role of FcγRIIa (CD32) in assessment of functional anti-Streptococcus pneumoniae antibody activity in human sera. J Infect Dis 1999;179:423-33.
36. 36. Sanders LA, van de Winkel JGJ, Rijkers GT, et al. Fcγ receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis 1994;170:854-61.
37. 37. Musher DM, Groover JE, Watson DA, et al. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J Investig Med 1997;45:57-68.
38. 38. Ortqvist A, Hedlund J, Burman LG, et al. Randomized trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351:399-403.
39. 39. Kenny GE, Wentworth BB, Beasley RP, Foy HM. Correlation of circulating capsular polysaccharide with bacteremia in pneumococcal pneumonia. Infect Immun 1972;6:431-7.
40. 40. Mellencamp MA, Preheim LC, McDonald TL. Isolation and characterization of circulating immune complexes from patients with pneumococcal pneumonia. Infect Immun 1987;55:1737-42.
41. 41. Holloway Y, Snijder JA, Boersma WG. Demonstration of circulating pneumococcal immunoglobulin G immune complexes in patients with community-acquired pneumonia by means of an enzyme-linked immunosorbent assay. J Clin Microbiol 1993;31:3247-54.